The proinflammatory cytokines IL-1β and TNF-α induce the expression of Synoviolin, an E3 ubiquitin ligase, in mouse synovial fibroblasts via the Erk1/2-ETS1 pathway

被引:64
作者
Gao, Beixue
Calhoun, Karen
Fang, Deyu
机构
[1] Univ Missouri, Sch Med, Dept Otolaryngol Head & Neck Surg, Columbia, MO 65212 USA
[2] Univ Missouri, Sch Med, Dept Mol Microbiol & Immunol, Columbia, MO 65212 USA
关键词
D O I
10.1186/ar2081
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
The overgrowth of synovial tissues is critical in the pathogenesis of rheumatoid arthritis (RA). The expression of Synoviolin (SYN), an E3 ubiquitin ligase, is upregulated in arthritic synovial fibroblasts and is involved in the overgrowth of synovial cells during RA. However, the molecular mechanisms involved in the elevated SYN expression are not known. Here, we found that SYN expression is elevated in the synovial fibroblasts from mice with collagen-induced arthritis (CIA). The proinflammatory cytokines interleukin (IL)-1 beta and tumor necrosis factor-alpha (TNF alpha) induce SYN expression in mouse synovial fibroblasts. Cultivation of mouse synovial fibroblasts with IL-1 beta activates mitogen-activated protein kinases, including extra-cellular signal-regulated kinase (Erk), JNK (c-Jun N-terminal kinase), and p38, while only Erk-specific inhibitor blocks IL-1 beta-induced SYN expression. Expression of transcription factor ETS1 further enhances IL-1 beta-induced SYN expression. The dominant negative ETS1 mutant lacking the transcription activation domain inhibits SYN expression in a dose-dependent manner. The activation of both Erk1/2 and ETS1 is increased in the CIA synovial fibroblasts. Inhibition of Erk activation reduces ETS1 phosphorylation and SYN expression. Our data indicate that the proinflammatory cytokines IL-1 beta and TNF-alpha induce the overgrowth of synovial cells by upregulating SYN expression via the Erk1/-ETS1 pathway. These molecules or pathways could therefore be potential targets for the treatment of RA.
引用
收藏
页数:10
相关论文
共 40 条
[1]
Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy [J].
Amano, T ;
Yamasaki, S ;
Yagishita, N ;
Tsuchimochi, K ;
Shin, H ;
Kawahara, K ;
Aratani, S ;
Fujita, H ;
Zhang, L ;
Ikeda, R ;
Fujii, R ;
Miura, N ;
Komiya, S ;
Nishioka, K ;
Maruyama, I ;
Fukamizu, A ;
Nakajima, T .
GENES & DEVELOPMENT, 2003, 17 (19) :2436-2449
[2]
Migration inhibitory factor mediates angiogenesis via mitogen-activated protein kinase and phosphatidylinositol kinase [J].
Amin, MA ;
Volpert, OV ;
Woods, JM ;
Kumar, P ;
Harlow, LA ;
Koch, AE .
CIRCULATION RESEARCH, 2003, 93 (04) :321-329
[3]
Identification of the critical features of a small peptide inhibitor of JNK activity [J].
Barr, RK ;
Kendrick, TS ;
Bogoyevitch, MA .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (13) :10987-10997
[4]
Hrd1p/Der3p is a membrane-anchored ubiquitin ligase required for ER-associated degradation [J].
Bays, NW ;
Gardner, RG ;
Seelig, LP ;
Joazeiro, CA ;
Hampton, RY .
NATURE CELL BIOLOGY, 2001, 3 (01) :24-29
[5]
Chen V, 1998, BRIT J RHEUMATOL, V37, P148
[6]
Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis [J].
Cunnane, G ;
Warnock, M ;
Fye, KH ;
Daikh, DI .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2002, 47 (04) :445-449
[7]
Pyrroles and other heterocycles as inhibitors of p38 kinase [J].
de Laszlo, SE ;
Visco, D ;
Agarwal, L ;
Chang, L ;
Chin, J ;
Croft, G ;
Forsyth, A ;
Fletcher, D ;
Frantz, B ;
Hacker, C ;
Hanlon, W ;
Harper, C ;
Kostura, M ;
Li, B ;
Luell, S ;
MacCoss, M ;
Mantlo, N ;
O'Neill, EA ;
Orevillo, C ;
Pang, M ;
Parsons, J ;
Rolando, A ;
Sahly, Y ;
Sidler, K ;
Widmer, WR ;
O'Keefe, SJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (19) :2689-2694
[8]
Dysregulation of T lymphocyte function in itchy mice:: a role for itch in TH2 differentiation [J].
Fang, DY ;
Elly, C ;
Gao, BX ;
Fang, N ;
Altman, Y ;
Joazeiro, C ;
Hunter, T ;
Copeland, N ;
Jenkins, N ;
Liu, YC .
NATURE IMMUNOLOGY, 2002, 3 (03) :281-287
[9]
Firestein GS, 1999, ARTHRITIS RHEUM-US, V42, P609, DOI 10.1002/1529-0131(199904)42:4<609::AID-ANR3>3.0.CO
[10]
2-I